Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis
- 23 March 2026
- journal article
- review article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (4) , 1-9
Abstract
Background Incidental prostate cancer (IPC) is not uncommon in patients undergoing surgery for benign prostate enlargement (BPE). However, the associated risk factors remain incompletely understood. This study aimed to evaluate potential clinical predictors of IPC. Methods A systematic search of MEDLINE, Embase, and Web of Science was conducted in January 2025 to identify studies assessing risk factors for IPC. Pairwise meta-analyses were performed using a random-effects model, pooling adjusted odds ratios (ORs) and 95% confidence intervals (CIs) from multivariable analyses. Risk of bias was evaluated using the ROBINS-I tool. (PROSPERO: CRD42024588776). Results Twenty-five studies comprising 247,966 patients were included. IPC was identified in 6,748 patients, with reported rates ranging from 2.2% to 49.6%. Significant risk factors for IPC included: Elevated PSA level (OR: 1.03; 95% CI: 1.01–1.05; p = 0.01), PSA density >0.15 ng/mL/cc (OR: 3.02; 95% CI: 1.50–6.07; p = 0.01), Older age (OR: 1.05; 95% CI: 1.01–1.08; p = 0.01), and Higher body mass index (BMI) (OR: 1.10; 95% CI: 1.02–1.18; p = 0.01). Prostate volume, diabetes, and dyslipidemia were not associated with IPC risk. Notably, use of 5-alpha reductase inhibitors (5-ARIs) was linked to a significantly reduced risk (OR: 0.53; 95% CI: 0.33–0.85; p = 0.01). Study limitations included heterogeneity across studies, retrospective designs, and incomplete reporting of key variables. Conclusions Elevated PSA, high PSA density, older age, and increased BMI were associated with a higher risk of IPC in patients undergoing surgery for BPE. Conversely, preoperative use of 5-ARIs was associated with a reduced risk. These findings may support improved preoperative risk stratification and help identify patients in whom additional diagnostic evaluations could be considered or avoided. Further research is needed to better define predictors of clinically significant IPC.Keywords
This publication has 51 references indexed in Scilit:
- Endoscopic enucleation of the prostate in men aged 80 years and older. Outcomes from a global, large, and multicenter series using different energy sources and techniquesWorld Journal of Urology, 2025
- Modern predictors and management of incidental prostate cancer at holmium enucleation of prostateThe Prostate, 2024
- Incidental prostate cancer after holmium laser enucleation of the prostate: Critical analysis of independent risk factors and impact on surgical outcomesBJUI Compass, 2023
- Incidence and associated factors for incidental prostate cancer among patients who underwent surgery for benign prostatic hyperplasia: first report from SomaliaJournal of Cancer Research and Clinical Oncology, 2022
- Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progressionInternational Journal of Clinical Oncology, 2022
- Incidence, predictive factors and oncological outcomes of incidental prostate cancer after endoscopic enucleation of the prostate: a systematic review and meta-analysisWorld Journal of Urology, 2021
- Association between PSA density and pathologically significant prostate cancer: The impact of prostate volumeThe Prostate, 2020
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- “Finding the needle in a haystack”: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP)World Journal of Urology, 2017
- PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasiaJournal of Surgical Oncology, 2011